From the therapeutic class to the clinical paradigm to the two distribution tiers and the delivery platforms that carry them. The taxonomy of the discipline.
The compounds of endogenic pharmacology. Short peptide bioregulators of the Khavinson lineage, and the proprietary trade-named portfolio u2014 Telogenixu2122, Thymogenixu2122, Vasogenixu2122, Dermogenixu2122, Cortigenixu2122, Lymphogenixu2122, and Gonadogenixu2122.
Read →The clinical practice of endogenic pharmacology. Translates the principles of endogenous regulation into therapeutic protocols across neurological, immune, vascular, longevity, and metabolic indications.
Read →Bioregulator-based products formulated for over-the-counter consumer access. Topical, transdermal, intranasal, sublingual, and oral delivery formats supporting wellness, longevity, and tissue-specific maintenance.
Read →Bioregulator-based therapeutics formulated for prescription clinical use. Pharmacy-compounded and FDA-pathway preparations for clinically supervised endogenic intervention.
Read →The branded delivery technologies of endogenic pharmacology. Twenty-two patent-pending platforms organized across oral and mucosal, topical and transdermal, parenteral and surgical, advanced and nanocarrier, and specialty verticals — each applicable across the bioregulator therapeutic class.
Read →